![]() The necessary duration of treatment for PD in patients responding to XANAX is unknown. In a controlled postmarketing dose-response study, patients treated with doses of XANAX greater than 4 mg per day for 3 months were able to taper to 50% of their total maintenance dose without apparent loss of clinical benefit. Occasional patients required as much as 10 mg per day.įor patients receiving doses greater than 4 mg per day, periodic reassessment and consideration of dosage reduction is advised. The mean dosage was approximately 5 mg to 6 mg daily. Depending on the response, the dosage may be increased at intervals of every 3 to 4 days in increments of no more than 1 mg per day.Ĭontrolled trials of XANAX in the treatment of panic disorder included dosages in the range of 1 mg to 10 mg daily. The recommended starting oral dosage of XANAX for the treatment of PD is 0.5 mg three times daily. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue XANAX or reduce the dosage. Abrupt discontinuation or rapid dosage reduction of XANAX after continued use may precipitate acute withdrawal reactions, which can be life-threatening. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. ![]() The continued use of benzodiazepines, including XANAX, may lead to clinically significant physical dependence.Before prescribing XANAX and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. The use of benzodiazepines, including XANAX, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death.Follow patients for signs and symptoms of respiratory depression and sedation. Limit dosages and durations to the minimum required. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. ![]() WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS ABUSE, MISUSE, AND ADDICTION and DEPENDENCE AND WITHDRAWAL REACTIONS Abrupt discontinuation or rapid dosage reduction of XANAX after continued use may precipitate acute withdrawal reactions, which can be life-threatening. ![]() Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate. WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS ABUSE, MISUSE, AND ADDICTION and DEPENDENCE AND WITHDRAWAL REACTIONS See full prescribing information for complete boxed warning. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |